Japanese Journal of Lung Cancer最新文献

{"title":"Perspective on Perioperative Therapy Using Immune Checkpoint Inhibitors","authors":"H. Horinouchi","doi":"10.2482/haigan.63.2","DOIUrl":"https://doi.org/10.2482/haigan.63.2","url":null,"abstract":"","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48571444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thyroid Transcription Factor-1, Tumor Proportion Score and Treatment Effect in Combination Therapy with Carboplatin, Pemetrexed, and Pembrolizumab as a First-line Therapy","authors":"F. Okabe, Shingo Sato, T. Yanase, Takatoshi Higuchi, K. Komuta, N. Morishita, K. Kawahara, Hidekazu Suzuki","doi":"10.2482/haigan.63.15","DOIUrl":"https://doi.org/10.2482/haigan.63.15","url":null,"abstract":"","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47955977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Malignant Pleural Mesothelioma Recurring 10 Years After a Long-term Response to Chemotherapy","authors":"Keisuke Hashida, K. Otsuka, Yuya Tanaka, T. Inao, K. Monden, Taiki Masuya, Takashi Tashiro, Rieko Ito, Yujiro Suzuki","doi":"10.2482/haigan.63.45","DOIUrl":"https://doi.org/10.2482/haigan.63.45","url":null,"abstract":"","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46119093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Osimertinib for EGFR Exon 20 Insertion Mutation-positive Non-small Cell Lung Cancer with Brain Metastases in a Very Elderly Man","authors":"Y. Kakiuchi, T. Satoh, R. Nakai","doi":"10.2482/haigan.63.33","DOIUrl":"https://doi.org/10.2482/haigan.63.33","url":null,"abstract":"","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44899524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Lung Typical Carcinoid in a Patient with Spontaneous Regression Who Showed Peripheral Eosinophilia and Eosinophilic Pleural Effusion","authors":"Ryusuke Maruta, Naoki Nishiyama, Masatake Kitano, Satoshi Chonabayashi, Shuhei Matsumoto, Masahiro Masuo, Hiroki Ebana, Aki Kobayashi, M. Otsuji, Masayoshi Kobayashi","doi":"10.2482/haigan.62.1026","DOIUrl":"https://doi.org/10.2482/haigan.62.1026","url":null,"abstract":"━━ Background. Lung typical carcinoids with spontaneous regression or paraneoplastic syndromes other than carcinoid syndromes are relatively rare. Case. A 69-year-old man was found to have a chest abnormal-ity during a medical checkup. Chest computed tomography (CT) showed nodules in the right S 5 and 8/9th inter-costal space and a mass in the right parietal pleura, near the 9-10th thoracic spine. The paravertebral mass re-gressed on chest CT, but right pleural effusion appeared three months later. He was transferred to our hospital and found to have peripheral eosinophilia and eosinophilic pleural effusion. A CT-guided biopsy was performed, as chest CT showed an increase in the size of the nodule at the right chest wall. However, the diagnosis was difficult due to an insufficient sample volume, and thoracoscopic partial lung resection with pleural tumor resection was performed. The histopathological samples showed tumor cells that were positive for neuroendocrine markers. The cell division was extremely low, and the patient was diagnosed with lung typical carcinoid (pT1cN0M1a pStage IVA). After resection, the peripheral eosinophilia improved spontaneously, and the right pleural effusion did not relapse. Despite the advanced stage, the target lesion was resected, and careful follow-up is being con-ducted. Conclusion. We experienced a very rare case of a patient with lung typical carcinoid with spontaneous regression and paraneoplastic syndromes.","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42644345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of Treatment-resistant Advanced Lung Cancer in a Patient with HIV Infection","authors":"Ippei Miyamoto, Tetsuo Shimizu, Shunji Yokota, Yuji Yamakawa, Haruyasu Sakuranaka, K. Igei, N. Okamoto, Y. Gon","doi":"10.2482/haigan.62.1033","DOIUrl":"https://doi.org/10.2482/haigan.62.1033","url":null,"abstract":"━━ Background. Antiretroviral therapy has been introduced to improve the prognosis of patients with human immunodeficiency virus (HIV) infection, and as a result, non-AIDS-defining cancer (NADC) may af-fect the prognosis. It has been shown that lung cancer patients with HIV progress faster in comparison to patients without HIV, and have a poor prognosis; however, there is no specific treatment protocol for lung cancer in patients with HIV. Case. The patient was a 55-year-old man who was diagnosed with advanced lung adenocarci-noma and infected with HIV. Platinum-based chemotherapy was administered, but the effect was poor, and docetaxel was started as the next treatment. He then showed prolonged myelosuppression, and his general condi-tion worsened, making it difficult to continue chemotherapy. Conclusion. We report a case of advanced lung cancer in a patient with HIV infection. It is hoped that standard chemotherapy for advanced lung cancer with HIV infection will be established.","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47533939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Indocyanine Green Injection into the Bronchial Wall Was Useful as a Central Side Marker in Resecting Small Lung Cancer","authors":"K. Araki, Y. Hirano, Naohiro Hayashi, C. Matsumoto, Masayuki Yasugi, G. Ikeda, Yoshiko Ogata, K. Gemba, K. Washio","doi":"10.2482/haigan.62.1014","DOIUrl":"https://doi.org/10.2482/haigan.62.1014","url":null,"abstract":"━━ Background. Markers are required for partial resection of tumors that are difficult to identify in-traoperatively. Virtual-assisted lung mapping (VAL-MAP) achieves simultaneous multiple mapping on the lung surface, enabling the resection range to be simulated more accurately than with conventional marking. Indocyanine green (ICG) gives good visibility as the dye used in VAL-MAP. However, since VAL-MAP cannot be used as a central side marker, there is a risk of the surgical margin of the central side closing. We attempted to use ICG injected into the bronchial wall as a central side marker. Case. In an 87-year-old woman who had undergone right lung S 1 ＋ 2 a segmentectomy for adenocarcinoma six years earlier, a new ground-glass nodule appeared, and wedge resection was planned for the diagnosis and treatment. Three mappings were placed on the lung surface using ICG-VAL-MAP, and ICG was injected into the bronchial wall of B 4 b on the central side of the tumor. During the operation, the bronchial-injected ICG was confirmed in the interlobar fissure with near-infrared fluorescence im-aging, and wedge resection was performed using this as a deep marker. The resection margin was 2.2 cm. No ad-verse events were observed. Conclusion. ICG injected into the bronchial wall can serve as a central side marker.","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44220056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two Cases of Retroperitoneal Fibrosis During Anti-programmed Cell Death 1 Antibody Treatment","authors":"Koichi Fujiu, Y. Utsumi, Fumito Omi, Motohisa Suzuki, Hiroyuki Suzuki","doi":"10.2482/haigan.62.1044","DOIUrl":"https://doi.org/10.2482/haigan.62.1044","url":null,"abstract":"━━ Background. Retroperitoneal fibrosis is characterized by fibrosis around the abdominal aorta and iliac arteries. Two-thirds of reported cases had idiopathic causes. Idiopathic retroperitoneal fibrosis is thought to result from a local inflammatory reaction to antigens in the atherosclerotic plaques of the abdominal aorta. Therefore, it is thought that idiopathic retroperitoneal fibrosis may be a manifestation of a systemic autoimmune or inflammatory disease. In contrast, antiprogrammed cell death 1 ( anti-PD-1 ) antibodies may overexpress innate immunity. There have been only two case reports on retroperitoneal fibrosis during antiPD-1 antibody treatment. We encountered two cases of retroperitoneal fibrosis during anti-PD-1 antibody treatment. Cases. Case 1 involved a 57-year-old man who experienced recurrence of squamous cell lung carcinoma after resection. More than 75% of his cancer cells were positive for programmed cell death ligand 1 (PD-L1). He experienced urinary urgency after one year and six months of nivolumab treatment. Computed tomography revealed a homogeneous plaque that was isodense with muscle surrounding the abdominal aorta and iliac arteries. Positron emission tomography revealed the accumulation of fluorodeoxyglucose at the same site. The serum IgG4 level was normal. Although a biopsy specimen was not obtained, the patient was diagnosed with retroperitoneal fibrosis. The patient was treated with steroids. Case 2 involved a 64-year-old man with pulmonary large cell carcinoma. An analysis of the cancer cells revealed that 50-74% of the cells were positive for PD-L1. Lower back pain appeared after one year and 11 months of pembrolizumab treatment. Computed tomography revealed right hydronephrosis and homogeneous plaque on the right side of the abdominal aorta. Although a biopsy specimen was not obtained, the patient was diagnosed with retroperitoneal fibrosis. The patient improved once with steroids but relapsed. Conclusion. We hypothesized that the administration of anti-PD-1 antibodies may have affected the onset of retroperitoneal fibrosis. (JJLC. 2022;62:1044-1047)","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47547455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Long-term Prognosis in Patients with Resected Stage IA Non-small-cell Lung Cancer","authors":"Shun-Ichi Watanabe","doi":"10.2482/haigan.62.971","DOIUrl":"https://doi.org/10.2482/haigan.62.971","url":null,"abstract":"━━ In recent years, long-term prognostic observations of five years or more for early-stage lung cancer have revealed that deaths from other diseases (secondary cancer deaths+non-cancer deaths) account for a considerable proportion of all deaths. In the era of medical advances, achieving a survival of five years after surgery is not the only goal for early-stage lung cancer, for which a good long-term prognosis can be expected. In the future, details of other disease deaths, i.e. what kind of cancer the patients suffered from and what kind of treatment they received in cases of death due to secondary cancers, or what kind of disease led to death due to non-cancer disease, should be confirmed over a much longer period of time than before. Given the above, we thoracic oncologists should evaluate how surgery, adjuvant chemotherapy, or adjuvant radiotherapy affect the long-term events (more than five years after treatment) and re-consider and improve our current treatment strategy prop-erly. ( JJLC. 2022;62:971-974)","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43003250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"121st Chubu Chapter Meeting","authors":"","doi":"10.2482/haigan.62.1066","DOIUrl":"https://doi.org/10.2482/haigan.62.1066","url":null,"abstract":"","PeriodicalId":35081,"journal":{"name":"Japanese Journal of Lung Cancer","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44621528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}